BACKGROUND AND OBJECTIVE: Effectiveness of recall for immunizations has not been examined in the setting of school-based health centers (SBHCs). We assessed (1) immunization rates achieved with recall among sixth-grade girls (demonstration study); (2) effectiveness of recall among sixth-grade boys (randomized controlled trial [RCT]); and (3) cost of conducting recall in SBHCs. METHODS: During October 2008 through March 2009, in 4 Denver public SBHCs, we conducted (1) a demonstration study among 265 girls needing ≥ 1 recommended adolescent vaccine and (2) an RCT among 264 boys needing vaccines, with half randomized to recall and half receiving usual care. Immunization rates for recommended adolescent vaccines were assessed 6 months after recall. First dose costs were assessed by direct observation and examining invoices. RESULTS: At the end of the demonstration study, 77% of girls had received ≥ 1 vaccine and 45% had received all needed adolescent vaccines. Rates of receipt among those needing each of the vaccines were 68% (160/236) for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, 57% (142/248) for quadrivalent meningococcal conjugate vaccine, and 59% (149/253) for the first human papillomavirus vaccine. At the end of the RCT, 66% of recalled boys had received ≥ 1 vaccine and 59% had received all study vaccines, compared with 45% and 36%, respectively, of the control group (P < .001). Cost of conducting recall ranged from $1.12 to $6.87 per recalled child immunized. CONCLUSIONS: SBHC-based recall was effective in improving immunization rates for all adolescent vaccines, with effects sizes exceeding those achieved with younger children in practice settings.
RCT Entities:
BACKGROUND AND OBJECTIVE: Effectiveness of recall for immunizations has not been examined in the setting of school-based health centers (SBHCs). We assessed (1) immunization rates achieved with recall among sixth-grade girls (demonstration study); (2) effectiveness of recall among sixth-grade boys (randomized controlled trial [RCT]); and (3) cost of conducting recall in SBHCs. METHODS: During October 2008 through March 2009, in 4 Denver public SBHCs, we conducted (1) a demonstration study among 265 girls needing ≥ 1 recommended adolescent vaccine and (2) an RCT among 264 boys needing vaccines, with half randomized to recall and half receiving usual care. Immunization rates for recommended adolescent vaccines were assessed 6 months after recall. First dose costs were assessed by direct observation and examining invoices. RESULTS: At the end of the demonstration study, 77% of girls had received ≥ 1 vaccine and 45% had received all needed adolescent vaccines. Rates of receipt among those needing each of the vaccines were 68% (160/236) for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, 57% (142/248) for quadrivalent meningococcal conjugate vaccine, and 59% (149/253) for the first human papillomavirus vaccine. At the end of the RCT, 66% of recalled boys had received ≥ 1 vaccine and 59% had received all study vaccines, compared with 45% and 36%, respectively, of the control group (P < .001). Cost of conducting recall ranged from $1.12 to $6.87 per recalled child immunized. CONCLUSIONS: SBHC-based recall was effective in improving immunization rates for all adolescent vaccines, with effects sizes exceeding those achieved with younger children in practice settings.
Authors: Alexander G Fiks; Robert W Grundmeier; Stephanie Mayne; Lihai Song; Kristen Feemster; Dean Karavite; Cayce C Hughes; James Massey; Ron Keren; Louis M Bell; Richard Wasserman; A Russell Localio Journal: Pediatrics Date: 2013-05-06 Impact factor: 7.124
Authors: Peter G Szilagyi; Christina Albertin; Sharon G Humiston; Cynthia M Rand; Stanley Schaffer; Howard Brill; Joseph Stankaitis; Byung-Kwang Yoo; Aaron Blumkin; Shannon Stokley Journal: Acad Pediatr Date: 2013-01-09 Impact factor: 3.107
Authors: Allison Kempe; Sean T O'Leary; Jo Ann Shoup; Shannon Stokley; Steven Lockhart; Anna Furniss; L Miriam Dickinson; Juliana Barnard; Matthew F Daley Journal: Pediatrics Date: 2016-02-26 Impact factor: 7.124
Authors: Jennifer S Smith; Noel T Brewer; Debbie Saslow; Kenneth Alexander; Mildred R Chernofsky; Richard Crosby; Libby Derting; Leah Devlin; Charles J Dunton; Jeffrey Engle; Maria Fernandez; Mona Fouad; Warner Huh; Walter Kinney; Jennifer Pierce; Elena Rios; Mitchel C Rothholz; Judith C Shlay; Rivienne Shedd-Steele; Sally W Vernon; Joan Walker; Theresa Wynn; Gregory D Zimet; Baretta R Casey Journal: Cancer Causes Control Date: 2013-07-05 Impact factor: 2.506
Authors: Timothy R Peters; Beverly M Snively; Cynthia K Suerken; Elizabeth Blakeney; Lauren Vannoy; Katherine A Poehling Journal: Vaccine Date: 2014-10-01 Impact factor: 3.641
Authors: Julie C Jacobson Vann; Robert M Jacobson; Tamera Coyne-Beasley; Josephine K Asafu-Adjei; Peter G Szilagyi Journal: Cochrane Database Syst Rev Date: 2018-01-18